Recent progress in gene therapy for Parkinson's disease

Current Molecular Medicine

Volumn 12, Issue 10, 2012, Pages 1311-1318

  Nakata, Y ^a   Yasuda, T ^a,b   Mochizuki, H ^a,b,c  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c KITASATO UNIVERSITY   (Japan)

Author keywords

Adeno associated virus; Aromatic L amino acid decarboxylase; Gene therapy; Glial cell line derived neurotrophic factor; Glutamic acid decarboxylase; Neurturin; Parkinson's disease

Indexed keywords

ADENOVIRUS VECTOR; AROMATIC LEVO AMINO ACID DECARBOXYLASE; CERE 120; DOPAMINE; FLUORODEOXYGLUCOSE F 18; GLUTAMATE DECARBOXYLASE; GUANOSINE TRIPHOSPHATE CYCLOHYDROLASE I; LENTIVIRUS VECTOR; LEVODOPA; NEURTURIN; NLX P 101; PLACEBO; PROSAVIN; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ARTICLE; BRAIN HEMORRHAGE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DYSKINESIA; HUMAN; LOW DRUG DOSE; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; NONHUMAN; PARKINSON DISEASE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; VIRAL GENE THERAPY;

AROMATIC-L-AMINO-ACID DECARBOXYLASES; DEPENDOVIRUS; DOPAMINE AGONISTS; DOPAMINERGIC NEURONS; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; GLUTAMATE DECARBOXYLASE; GTP CYCLOHYDROLASE; HUMANS; INFECTIOUS ANEMIA VIRUS, EQUINE; LEVODOPA; NEURTURIN; PARKINSON DISEASE; TYROSINE 3-MONOOXYGENASE;

ADENO-ASSOCIATED VIRUS; ADENO-ASSOCIATED VIRUS - 2; EQUINE INFECTIOUS ANEMIA VIRUS;

EID: 84870153310     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/156652412803833580     Document Type: Article

References (51)

1. Van Den Eeden SK, Tanner CM, Bernstein AL, et al. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am J Epidemiol 2003; 157: 1015-1022.
2. ankovic J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 2008; 79: 368-376.
3. Gleichgerrcht E, Ibanez A, Roca M, Torralva T, Manes F. Decision-making cognition in neurodegenerative diseases. Nat Rev Neurol 2010; 6: 611-623.
4. Xiao X, Li J, McCown TJ, Samulski RJ. Gene transfer by adeno-associated virus vectors into the central nervous system. Exp Neurol 1997; 144: 113-124.
5. Goverdhana S, Puntel M, Xiong W, et al. Regulatable gene expression systems for gene therapy applications: progress and future challenges. Mol Ther 2005; 12: 189-211.
6. Mitrophanous K, Yoon S, Rohll J, et al. Stable gene transfer to the nervous system using a non-primate lentiviral vector. Gene Ther 1999; 6: 1808-1818.
7. Azzouz M, Kingsman SM, Mazarakis ND. Lentiviral vectors for treating and modeling human CNS disorders. J Gene Med 2004; 6: 951-962.
8. Bowers WJ, Olschowka JA, Federoff HJ. Immune responses to replication-defective HSV-1 type vectors within the CNS: implications for gene therapy. Gene Ther 2003; 10: 941-945.
9. Hackett NR, Kaminsky SM, Sondhi D. Antivector and antitransgene host responses in gene therapy. Curr Opin Mol Ther 2000; 2: 376-382.
10. Nagatsu T, Sawada M. L-dopa therapy for Parkinson's disease: past, present, and future. Parkinsonism Relat Disord 2009; 15 Suppl 1: S3-8.
11. Elsworth JD, Roth RH. Dopamine synthesis, uptake, metabolism, and receptors: relevance to gene therapy of Parkinson's disease. Exp Neurol 1997; 144: 4-9.
12. Rascol O, Payoux P, Ory F, Ferreira JJ, Brefel-Courbon C, Montastruc JL. Limitations of current Parkinson's disease therapy. Ann Neurol 2003; 53: S3-S12.
13. Nagatsu T, Sawada M. Biochemistry of postmortem brains in Parkinson's disease: historical overview and future prospects. J Neural Transm Suppl 2007; 72: 113-120.
14. An DS, Ogawa M, Fujimoto KI, et al. Behavioral recovery in 6-hydroxydopamine-lesioned rats by cotransduction of striatum with tyrosine hydroxylase and aromatic L-amino acid decarboxylase genes using two separate adeno-associated virus vectors. Hum Gene Ther 1998; 9: 2527-2535.
15. Imaoka T, Date I, Ohmoto T, Nagatsu T. Significant behavioral recovery in Parkinson's disease model by direct intracerebral gene transfer using continuous injection of a plasmid DNA-liposome complex. Hum Gene Ther 1998; 9: 1093-1102.
16. Bankiewicz KS, Eberling JL, Kohutnicka M, et al. Convectionenhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach. Exp Neurol 2000; 164: 2-14.
17. Forsayeth JR, Eberling JL, Sanftner LM, et al. A doseranging study of AAV-hAADC therapy in Parkinsonian monkeys. Mol Ther 2006; 14: 571-577.
18. Eberling JL, Jagust WJ, Christine CW, et al. Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology 2008; 70: 1980-1983.
19. Christine CW, Starr PA, Larson PS, et al. Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology 2009; 73: 1662-1669.
20. Muramatsu S, Fujimoto K, Kato S, et al. A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson's disease. Mol Ther 2010; 18: 1731-1735.
21. Sanofi-aventis Press Release: Sanofi-Aventis Completes Acquisition of Genzyme Corporation. Available at: http://www.genzyme.com/corp/investors/SA_040811_ENG.pdf [accessed September 7, 2011].
22. Shen Y, Muramatsu SI, Ikeguchi K, et al. Triple transduction with adeno-associated virus vectors expressing tyrosine hydroxylase, aromatic-L-amino-acid decarboxylase, and GTP cyclohydrolase I for gene therapy of Parkinson's disease. Hum Gene Ther 2000; 11: 1509-1519.
23. Muramatsu S, Fujimoto K, Ikeguchi K, et al. Behavioral recovery in a primate model of Parkinson's disease by triple transduction of striatal cells with adeno-associated viral vectors expressing dopamine-synthesizing enzymes. Hum Gene Ther 2002; 13: 345-354.
24. Azzouz M, Martin-Rendon E, Barber RD, et al. Multicistronic lentiviral vector-mediated striatal gene transfer of aromatic Lamino acid decarboxylase, tyrosine hydroxylase, and GTP cyclohydrolase I induces sustained transgene expression, dopamine production, and functional improvement in a rat model of Parkinson's disease. J Neurosci 2002; 22: 10302-10312.
25. Jarraya B, Boulet S, Ralph GS, et al. Dopamine gene therapy for Parkinson's disease in a nonhuman primate without associated dyskinesia. Sci Transl Med 2009; 1: 1-11.
26. Oxford BioMedica Announces Presentation of New Clinical Data from ProSavin Phase I/II Study in Parkinsons Disease. Available at: http://www.oxfordbiomedica.co.uk/page.asp?pageid=59&newsid=292 [accessed September 7, 2011].
27. Bevan MD, Atherton JF, Baufreton J. Cellular principles underlying normal and pathological activity in the subthalamic nucleus. Curr Opin Neurobiol 2006; 16: 621-628.
28. Hamani C, Saint-Cyr JA, Fraser J, Kaplitt M, Lozano AM. The subthalamic nucleus in the context of movement disorders. Brain 2003; 127: 4-20.
29. Luo J, Kaplitt MG, Fitzsimons HL, et al. Subthalamic GAD gene therapy in a Parkinson's disease rat model. Science 2002; 298: 425-429.
30. Emborg ME, Carbon M, Holden JE, et al. Subthalamic glutamic acid decarboxylase gene therapy: changes in motor function and cortical metabolism. J Cereb Blood Flow Metab 2007; 27: 501-509.
31. Itzsimons HL, Riban V, Bland RJ, Wendelken JL, Sapan CV, During MJ. Biodistribution and safety assessment of AAV2-GAD following intrasubthalamic injection in the rat. J Gene Med 2010; 12: 385-398.
32. Kaplitt MG, Feigin A, Tang C, et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 2007; 369: 2097-2105.
33. LeWitt PA, Rezai AR, Leehey MA, et al. AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol 2011; 10: 309-319.
34. Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 1993; 260: 1130-1132.
35. Kirik D, Rosenblad C, Bjorklund A, Mandel RJ. Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system. J Neurosci 2000; 20: 4686-4700.
36. Horger BA, Nishimura MC, Armanini MP, et al. Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons. J Neurosci 1998; 18: 4929-4937.
37. Gasmi M, Brandon EP, Herzog CD, et al. AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-term efficacy and tolerability of CERE-120 for Parkinson's disease. Neurobiol Dis 2007; 27: 67-76.
38. Kordower JH, Herzog CD, Dass B, et al. Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys. Ann Neurol 2006; 60: 706-715.
39. Herzog CD, Brown L, Gammon D, et al. Expression, bioactivity, and safety 1 year after adeno-associated viral vector type 2-mediated delivery of neurturin to the monkey nigrostriatal system support cere-120 for Parkinson's disease. Neurosurgery 2009; 64: 602-613.
40. Hovland DN Jr, Boyd RB, Butt MT, et al. Six-month continuous intraputamenal infusion toxicity study of recombinant methionyl human glial cell line-derived neurotrophic factor (r-metHuGDNF) in rhesus monkeys, Toxicol Pathol 2007; 35: 1013-1029.
41. Marks WJ Jr, Ostrem JL, Verhagen L, et al. Safety and tolerability of intraputaminal delivery of CERE-120 (adenoassociated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol 2008; 7: 400-408.
42. Marks WJ Jr, Bartus RT, Siffert J, et al. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol 2010; 9: 1164-1172.
43. Bartus RT, Herzog CD, Chu Y, et al. Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains. Mov Disord 2011; 26: 27-36.
44. Dumitriu A, Popescu BO. Placebo effects in neurological diseases. J Med Life 2010; 3: 114-121.
45. de la Fuente-Fernandez R, Ruth TJ, Sossi V, Schulzer M, Calne DB, Stoessl AJ. Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease. Science 2001; 293: 1164-1166.
46. Freed CR, Greene PE, Breeze RE, et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 2001; 344: 710-719.
47. Olanow CW, Goetz CG, Kordower JH, et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 2003; 54: 403-414.
48. Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med 2008; 14: 504-506.
49. Li JY, Englund E, Holton JL, et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest hostto-graft disease propagation. Nat Med 2008; 14: 501-503.
50. Roy NS, Cleren C, Singh SK, Yang L, Beal MF, Goldman SA. Functional engraftment of human ES cell-derived dopaminergic neurons enriched by coculture with telomerase-immortalized midbrain astrocytes. Nat Med 2006; 12: 1259-1268.
51. Kawai H, Yamashita T, Ohta Y, et al. Tridermal tumorigenesis of induced pluripotent stem cells transplanted in ischemic brain. J Cereb Blood Flow Metab 2010; 30: 1487-1493.